Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting ...
Contineum Therapeutics’ M1 antagonist, PIPE-307, has failed to meet its primary and secondary efficacy endpoints in a Phase II trial in RRMS. Image credit: Andrzej Rostek via ShutterStock.com.
The trial is evaluating sabirnetug for early Alzheimer’s disease. Credit: Dragana Gordic / Shutterstock.com. Acumen Pharmaceuticals has dosed the first subject in the open-label extension (OLE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback